Medications

GlaxoSmithKline opts to hold on to HIV business

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

Medications

British drugmaker cutting hundreds of US jobs

Hundreds of British drugmaker GlaxoSmithKline's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring.

Neuroscience

Obama's BRAIN initiative gets more than $300 million

President Barack Obama's initiative to study the brain and improve treatment of conditions like Alzheimer's and autism was given a boost Tuesday with the announcement of more than $300 million in funds.

Other

Novartis cites momentum in three percent profit rise

Swiss pharmaceutical company Novartis AG posted a 3 percent rise in second-quarter profits Thursday, reflecting what it described as solid growth and an increased focus on core products.

page 7 from 18